Orhan E, Velazquez C, Tabet I, Fenou L, et al. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer. Cancer Lett 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820.
PMID: 38574883